Article

Effects of heroin-assisted treatment on alcohol consumption: Findings of the German randomized controlled trial

Department of Psychiatry, Centre for Interdisciplinary Addiction Research, University Medical Centre Eppendorf, Hamburg, Germany.
Alcohol (Fayetteville, N.Y.) (Impact Factor: 2.04). 05/2009; 43(4):259-64. DOI: 10.1016/j.alcohol.2009.02.007
Source: PubMed

ABSTRACT Alcohol has been suggested to be a risk factor for opioid-dependent patients in methadone maintenance treatment (MMT). Literature shows that MMT has limited effects on alcohol use. Nevertheless, a decrease in alcohol use was detected in the Swiss heroin-assisted treatment (HAT) study. In this article, we carry out an in-depth analysis of the German HAT trial with the aim of determining whether alcohol use was affected among patients undergoing HAT and MMT. Analysis was carried out using self-reported data on consumption units of alcohol used (CU), Addiction Severity Index composite scores (ASI CSs), and carbohydrate-deficient transferrin (CDT) measures. Results suggest significant reduction of CU and CDT in both groups, yet larger effects in the HAT group. ASI CS significantly decreased in the HAT but not in the MMT group. The greater benefit of HAT in reducing alcohol use may be due to the greater daily frequency of dispensing heroin coupled with a requirement of sobriety at each dosing occasion.

Download full-text

Full-text

Available from: Francisco Jose Eiroa Orosa, Aug 26, 2015
0 Followers
 · 
127 Views
  • Source
    • "There is increased retention in IOT/ HAT compared with control groups; reductions in self-reported illicit heroin use, and improved outcomes in terms of quality of life or health outcome measures. One study reported improved outcomes in relation to reduced consumption of alcohol (Haasen et al., 2009) (Ib). The Cochrane review by Ferri et al. (2011) (Ia) concluded that evidence suggested heroin alongside methadone for long-term, treatment refractory opioid users reduced illicit substance use and criminal activity and possibly reduced mortality and increased retention in treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
    Journal of Psychopharmacology 05/2012; 26(7):899-952. DOI:10.1177/0269881112444324 · 2.81 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite a lower prevalence of opioid dependence among females, drug-related problems and risk factors such as prostitution have a negative effect for women in treatment. This study was conducted with the purpose of analyzing gender differences in the German trial on heroin-assisted treatment (HAT), which compared HAT with methadone maintenance treatment (MMT). Significant baseline gender differences were found, with females showing a greater extent of mental distress. Differences in retention and outcome were significant for male patients, but no differences between treatment options were found for female patients. Ongoing prostitution was found to influence drug use outcomes. Other outcome criteria may need to be stressed when assessing the effect of HAT for women.
    American Journal on Addictions 05/2010; 19(4):312-8. DOI:10.1111/j.1521-0391.2010.00049.x · 1.74 Impact Factor
Show more